- Article
Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)
- Mahir Karakas,
- Dominik Jarczak,
- Martin Becker,
- Kevin Roedl,
- Marylyn M. Addo,
- Frauke Hein,
- Andreas Bergmann,
- Jens Zimmermann,
- Tim-Philipp Simon and
- Gernot Marx
- + 3 authors
Recently, the stabilization of the endothelium has been explicitly identified as a therapeutic goal in coronavirus disease 2019 (COVID-19). Adrecizumab (HAM8101) is a first-in-class humanized monoclonal anti-Adrenomedullin (anti-ADM) antibody, target...

